The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
Open accessPublished version of a preprint
Abstract
Chimeric antigen receptor (CAR)–modified T cells with anti-CD19 specificity are a highly effective novel immune therapy for relapsed/refractory acute lymphoblastic leukemia. Cytokine release syndrome (CRS) is the most significant and life-threatening toxicity. To improve understanding of CRS, we measured cytokines and clinical biomarkers in 51 CTL019-treated patients. Peak levels of 24 cytokines, including IFNγ, IL6, sgp130, and sIL6R, in the first month after infusion were highly associated with severe CRS. Using regression modeling, we could accurately predict which patients would develop severe CRS with a signature composed of three cytokines. Results were validated in an independent cohort. Changes in serum biochemical markers, including C-reactive protein and ferritin, were associated with CRS but failed to predict development of severe CRS. These comprehensive profiling data provide novel insights into CRS biology and, importantly, represent the first data that can accurately predict which patients have a high probability of becoming critically ill. Significance: CRS is the most common severe toxicity seen after CAR T-cell treatment. We developed models that can accurately predict which patients are likely to develop severe CRS before they become critically ill, which improves understanding of CRS biology and may guide future cytokine-directed therapy. Cancer Discov; 6(6); 664–79. ©2016 AACR. See related commentary by Rouce and Heslop, p. 579. This article is highlighted in the In This Issue feature, p. 561
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most severe of these immune-related adverse events (irAEs) are cytokine release syndrome (CRS) and neurotoxicity, most prominently described in patients treated with CAR-T-cells [6–11].”
From Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm (2021) · cites this paper as [7]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Immune checkpoint blockade induces irAEs during short-term follow-up of some patients with cancer, though robust immune biomarkers correlating with adverse effects of therapy are still being investigated [1, 4, 7, 20–25].”
From Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm (2021) · cites this paper as [7]
Experimental — accuracy not yet measuredIn the citing paper
“Serum biomarkers, including glycoprotein 130 (gp130), interferon-γ, and interleukin-1–receptor antagonist (IL1RA), can be used to predict the severity of cytokine storm induced by CAR T-cell therapy”
From Cytokine storm (2020) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Self-citationChimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Self-citationChimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Self-citationLee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Self-citationEfficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Self-citationRose-John, S. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4989 · Cited by 1,040 · cited 3×
“In other IL6-mediated diseases, IL6 levels often go up and sIL6R levels either increase or decrease after treatment as the interaction between IL6R and IL6 is blocked (21, 23, 24).”
BackgroundSelf-citationBorowitz, M. J., Devidas, M., Hunger, S. P., Bowman, W. P., Carroll, A. J., Carroll, W. L., Linda, S. B., Martin, P. L., Pullen, D. J., Viswanatha, D. S., et al. (2008) · Blood · doi:10.1182/blood-2008-01-132837 · Cited by 841
Cited by
Sorted by citations
Items 201–300 of 1,000
Promising approaches in cancer immunotherapy
Taefehshokr, N., Baradaran, B., Baghbanzadeh, A., & Taefehshokr, S. (2019) · Immunobiology · doi:10.1016/j.imbio.2019.11.010 · Cited by 94
Applying a clinical lens to animal models of CAR-T cell therapies
Duncan, B. B., Dunbar, C. E., & Ishii, K. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.08.008 · Cited by 99
Chou, C. K., & Turtle, C. J. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1729735 · Cited by 92
Yan, Z., Zhang, H.-X., Cao, J., Zhang, C., Liu, H., Huang, H., Cheng, H., Qiao, J., Wang, Y., Wang, Y., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.611366 · Cited by 93
Li, X., Shao, M., Zeng, X., Qian, P., & Huang, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00764-4 · Cited by 94
Arnaldez, F. I., O'Day, S. J., Drake, C. G., Fox, B. A., Fu, B., Urba, W. J., Montesarchio, V., Weber, J. S., Wei, H., Wigginton, J. M., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000930 · Cited by 92
Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma
Lin, L., Cho, S., Xing, L., Wen, K., Li, Y., Yu, T., Hsieh, P. A., Chen, H., Kurtoğlu, M., Zhang, Y., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0951-5 · Cited by 92
Clinical development of CAR T cell therapy in China: 2020 update
Wei, J., Guo, Y., Wang, Y., Wu, Z., Bo, J., Zhang, B., Zhu, J., & Han, W. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00555-x · Cited by 90
Ahmad, A., Shahab Uddin, M. S., & Steinhoff, M. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113906 · Cited by 91
Casucci, M., Falcone, L., Camisa, B., Norelli, M., Porcellini, S., Stornaiuolo, A., Ciceri, F., Traversari, C., Bordignon, C., Bonini, C., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00507 · Cited by 88
CAR T-Cell Therapy: Adverse Events and Management
Adkins, S. (2019) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2019.10.4.11 · Cited by 87
Kenderian, S. S., Porter, D. L., & Gill, S. I. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.09.002 · Cited by 86
Self-citationMontesarchio, V., Parrella, R., Iommelli, C., Bianco, A., Manzillo, E., Fraganza, F., Palumbo, C., Rea, G., Murino, P., Rosa, R. C. D., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001089 · Cited by 84
Biomarkers for Predicting Cytokine Release Syndrome following CD19-Targeted CAR T Cell Therapy
Tedesco, V. E., & Mohan, C. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001249 · Cited by 84
CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence
Wei, W., Chen, Z., & Wang, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512317 · Cited by 90
Kerns, S. J., Belgur, C., Petropolis, D., Kanellias, M., Barrile, R., Sam, J., Weinzierl, T., Fauti, T., Freimoser-Grundschober, A., Eckmann, J., et al. (2021) · eLife · doi:10.7554/elife.67106 · Cited by 82
Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities
Dholaria, B., Bachmeier, C. A., & Locke, F. L. (2018) · BioDrugs · doi:10.1007/s40259-018-0324-z · Cited by 83
Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies
Fishman, J. A., Hogan, J. I., & Maus, M. V. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy1025 · Cited by 83
Faramand, R. G., Jain, M. D., Staedtke, V., Kotani, H., Bai, R.-Y., Reid, K. M., Lee, S. B., Spitler, K., Wang, X., Cao, B., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1434 · Cited by 88
Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas
Salvaris, R., Ong, J., & Gregory, G. P. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11050355 · Cited by 83
Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment
Wang, Z., Guo, Y., & Han, W. (2017) · Protein & Cell · doi:10.1007/s13238-017-0400-z · Cited by 83
The Immunology of Hepatocellular Carcinoma
Lawal, G., Xiao, Y., Rahnemai‐Azar, A. A., Tsilimigras, D. I., Kuang, M., Bakopoulos, A., & Pawlik, T. M. (2021) · Vaccines · doi:10.3390/vaccines9101184 · Cited by 81
Quantitative Systems Pharmacology Model of Chimeric Antigen Receptor T‐Cell Therapy
Hardiansyah, D., & Ng, C. M. (2019) · Clinical and Translational Science · doi:10.1111/cts.12636 · Cited by 82
Li, C., Jiang, J., Wang, F., Zhou, N., Veronese, G., Moslehi, J. J., Ammirati, E., & Wang, D. W. (2020) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2020.08.008 · Cited by 82
TCR engineered T cells for solid tumor immunotherapy
Zhang, Y., Liu, Z., Wei, W., & Li, Y. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00291-0 · Cited by 81
Critical care management of chimeric antigen receptor T‐cell therapy recipients
Shimabukuro‐Vornhagen, A., Böll, B., Schellongowski, P., Valade, S., Metaxa, V., Azoulay, É., & von Bergwelt‐Baildon, M. (2021) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21702 · Cited by 81
Exploring CAR-T Cell Therapy Side Effects: Mechanisms and Management Strategies
Zhang, Y., Qin, D., Shou, A., Liu, Y., Wang, Y., & Zhou, L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196124 · Cited by 82
Wei, G., Ding, L., Wang, J., Hu, Y., & Huang, H. (2017) · Experimental Hematology and Oncology · doi:10.1186/s40164-017-0070-9 · Cited by 78
Elahi, R., Khosh, E., Tahmasebi, S., & Esmaeilzadeh, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01717 · Cited by 82
Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients
Ishii, K., Pouzolles, M., Chien, C. D., Erwin-Cohen, R. A., Kohler, M. E., Qin, H., Lei, H., Kuhn, S. A., Ombrello, A. K., Dulau‐Florea, A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci130059 · Cited by 77
Advanced Flow Cytometry Assays for Immune Monitoring of CAR-T Cell Applications
Blache, U., Weiss, R., Boldt, A., Kapinsky, M., Blaudszun, A., Quaiser, A., Pohl, A., Miloud, T., Burgaud, M., Vučinić, V., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658314 · Cited by 81
The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy
Fabian, K. P., & Hodge, J. W. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.10.001 · Cited by 77
Demaria, O., Gauthier, L., Vétizou, M., Blanchard-Alvarez, A., Vagne, C., Habif, G., Batista, L., Baron, W., Belaïd, N., Girard-Madoux, M. J. H., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100783 · Cited by 78
Luo, H., Wang, N., Huang, L., Zhou, X., Jin, J., Li, C., Wang, D., Xu, B., Xu, J., Jiang, L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0767-x · Cited by 74
Highways to hell: Mechanism-based management of cytokine storm syndromes
Canna, S., & Cron, R. Q. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.09.016 · Cited by 74
Beyond the storm — subacute toxicities and late effects in children receiving CAR T cells
Shalabi, H., Gust, J., Taraseviciute, A., Wolters, P. L., Leahy, A. B., Sandi, C., Laetsch, T. W., Wiener, L. S., Gardner, R. A., Nussenblatt, V. R., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00456-y · Cited by 74
Self-citationWei, G., Zhang, Y., Zhao, H., Wang, Y., Liu, Y., Liang, B., Wang, X., Xu, H., Cui, J., Wu, W., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0675 · Cited by 73
Setting the target for pemphigus vulgaris therapy
Ellebrecht, C. T., & Payne, A. S. (2017) · JCI Insight · doi:10.1172/jci.insight.92021 · Cited by 74
Building blocks for institutional preparation of CTL019 delivery
McGuirk, J. P., Waller, E. K., Qayed, M. D., Abhyankar, S., Ericson, S. G., Holman, P., Keir, C. H., & Myers, G. D. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2017.06.001 · Cited by 75
Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges
McKean, W. B., Moser, J. C., Rimm, D. L., & Hu‐Lieskovan, S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280571 · Cited by 74
Cardiotoxicity of Immune Therapy
Ganatra, S., Parikh, R. B., & Neilan, T. G. (2019) · Cardiology Clinics · doi:10.1016/j.ccl.2019.07.008 · Cited by 72
Cellular therapy: Immune‐related complications
Oved, J. H., Barrett, D. M., & Teachey, D. T. (2019) · Immunological Reviews · doi:10.1111/imr.12768 · Cited by 72
Self-citationCytokine Release Syndrome Biology and Management
Cobb, D. A., & Lee, D. W. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000515 · Cited by 71
Manni, S., Bufalo, F. D., Merli, P., Silvestris, D. A., Guercio, M., Caruso, S., Reddel, S., Iaffaldano, L., Pezzella, M., Cecca, S. D., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38723-y · Cited by 74
Kumar, B., Aleem, S., Saleh, H., Petts, J., & Ballas, Z. K. (2017) · Journal of Clinical Immunology · doi:10.1007/s10875-017-0439-x · Cited by 70
Kauer, J., Hörner, S., Osburg, L., Müller, S., Märklin, M., Heitmann, J. S., Zekri, L., Rammensee, H., Salih, H. R., & Jung, G. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000621 · Cited by 70
Koehler, F. C., Cristanziano, V. D., Späth, M. R., Hoyer-Allo, K. J. R., Wanken, M., Müller, R., & Burst, V. R. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac008 · Cited by 71
Diorio, C. J., Shraim, R., Myers, R. M., Behrens, E. M., Canna, S., Bassiri, H., Aplenc, R., Burudpakdee, C., Chen, F., DiNofia, A. M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0822 · Cited by 75
Self-citationHarnessing CD3 diversity to optimize CAR T cells
Cárdenas, R. M.-H. V., Brandl, S. M., Meléndez, A. V., Schlaak, A. E., Buschky, A., Peters, T., Beier, F., Serrels, B., Taromi, S., Raute, K., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01658-z · Cited by 72
Aldoss, I. T., Bargou, R. C., Nagorsen, D., Friberg, G. R., Baeuerle, P. A., & Forman, S. J. (2016) · Leukemia · doi:10.1038/leu.2016.391 · Cited by 70
Understanding cytokine release syndrome
Gödel, P., Shimabukuro‐Vornhagen, A., & von Bergwelt‐Baildon, M. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4943-5 · Cited by 72
Heng, G., Jia, J., Li, S., Fu, G., Wang, M., Qin, D., Li, Y., Li, P., Tian, X., Zhang, J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1339 · Cited by 70
Bruserud, Ø., Aarstad, H. H., & Tvedt, T. H. A. (2020) · Cancers · doi:10.3390/cancers12071966 · Cited by 69
CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies
Huang, J., Huang, X., & Huang, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1019115 · Cited by 72
Li, Y., Ming, Y., Fu, R., Li, C., Wu, Y., Jiang, T., Li, Z., Ni, R., Li, L., Su, H., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.950923 · Cited by 75
Gutiérrez, C., McEvoy, C. A., Mead, E., Stephens, R. S., Munshi, L., Detsky, M. E., Pastores, S. M., & Nates, J. L. (2018) · Critical Care Medicine · doi:10.1097/ccm.0000000000003258 · Cited by 70
Cerrano, M., Ruella, M., Perales, M., Vitale, C., Faraci, D., Giaccone, L., Coscia, M., Maloy, M., Sánchez‐Escamilla, M., Elsabah, H., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00888 · Cited by 71
Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You
Ruella, M., & June, C. H. (2016) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-016-0336-z · Cited by 68
Self-citationLin, H., Scull, B., Goldberg, B. R., Abhyankar, H. A., Eckstein, O. S., Zinn, D. J., Lubega, J., Agrusa, J. E., Mallawaney, N. E., Gulati, N., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004287 · Cited by 69
Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer
Sur, D. G., Havasi, A. D., Cainap, C. I., Samaşcă, G., Burz, C. C., Bălăcescu, O., Lupan, I., Deleanu, D. M., & Irimie, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010182 · Cited by 67
Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice
Li, T., & Wang, J. (2020) · BMC Cancer · doi:10.1186/s12885-020-07180-x · Cited by 67
Atilla, P. A., McKenna, M. K., Tashiro, H., Srinivasan, M., Mo, F., Watanabe, N., Simons, B. W., Stevens, A. M., Redell, M. S., Heslop, H. E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001229 · Cited by 68
Wu, J., Meng, F., Cao, Y., Zhang, Y., Zhu, X., Wang, N., Wang, J., Huang, L., Zhou, J., & Xiao, Y. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00523-2 · Cited by 67
CAR-T cell-derived exosomes: a new perspective for cancer therapy
Sani, F., Shojaei, S., Tabatabaei, S. A., Khorraminejad‐Shirazi, M., Latifi, M., Sani, M., & Azarpira, N. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03783-4 · Cited by 66
Jain, M. D., & Davila, M. L. (2017) · Stem Cells · doi:10.1002/stem.2715 · Cited by 67
Frigault, M. J., Nikiforow, S., Mansour, M. K., Hu, Z., Horowitz, M. M., Riches, M., Hematti, P., Turtle, C. J., Zhang, M., Perales, M., et al. (2020) · Blood · doi:10.1182/blood.2020006216 · Cited by 67
Coppola, C. D., Hopkins, B., Huhn, S. C., Du, Z., Huang, Z. J., & Kelly, W. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217814 · Cited by 65
Mechanisms of immune effector cell‐associated neurotoxicity syndrome after CAR‐T treatment
Gu, T., Hu, K., Si, X., Hu, Y., & Huang, H. (2022) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1576 · Cited by 69
CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges
Rendo, M. J., Joseph, J. J., Phan, L. M., & DeStefano, C. B. (2022) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s327016 · Cited by 68
Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia
Jin, C., Xia, J., Rafiq, S., Huang, X., Hu, Z., Zhou, X., Brentjens, R. J., & Yang, Y. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.013 · Cited by 65
McNerney, K. O., DiNofia, A. M., Teachey, D. T., Grupp, S. A., & Maude, S. L. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0203 · Cited by 71
Self-citationNovel strategies to manage CAR-T cell toxicity
Mulvey, A., Trueb, L., Coukos, G., & Arber, C. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01100-5 · Cited by 69
Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations
Xie, Y., Xiang, Y., Sheng, J., Zhang, D., Yao, X., Yang, Y., & Zhang, X. (2018) · Journal of Immunology Research · doi:10.1155/2018/8740976 · Cited by 62
Zhang, Y., Gu, H., & Xu, H. Y. (2023) · Sensors & Diagnostics · doi:10.1039/d3sd00144j · Cited by 63
Lokau, J., Agthe, M., & Garbers, C. (2016) · Mediators of Inflammation · doi:10.1155/2016/1785021 · Cited by 62
Diorio, C., Shaw, P. A., Pequignot, E., Orlenko, A., Chen, F., Aplenc, R., Barrett, D. M., Bassiri, H., Behrens, E., DiNofia, A. M., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002592 · Cited by 61
Self-citationNo free rides: management of toxicities of novel immunotherapies in ALL, including financial
Jain, T., & Litzow, M. R. (2018) · Hematology · doi:10.1182/asheducation-2018.1.25 · Cited by 61
Buechner, J., Grupp, S. A., Hiramatsu, H., Teachey, D. T., Rives, S., Laetsch, T. W., Yanik, G. A., Wood, P. A., Awasthi, R., Yi, L., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020002757 · Cited by 62
Self-citationXu, X., Huang, S., Xiao, X., Sun, Q., Liang, X., Chen, S., Zhao, Z., Huo, Z., Tu, S., & Li, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.569117 · Cited by 62
Tvedt, T. H. A., Vo, A. K., Bruserud, Ø., & Reikvam, H. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10215190 · Cited by 65
Castellanos-Rueda, R., Roberto, R. B. D., Bieberich, F., Schlatter, F. S., Palianina, D., Nguyen, O. T. P., Kapetanovic, E., Laubli, H. P., Hierlemann, A. R., Khanna, N., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34141-8 · Cited by 61
Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy
Hughes, A. D., Teachey, D. T., & Diorio, C. J. (2024) · Seminars in Immunopathology · doi:10.1007/s00281-024-01013-w · Cited by 69
Self-citationKlingström, J., Smed‐Sörensen, A., Maleki, K. T., Solà-Riera, C., Ahlm, C., Björkström, N. K., & Ljunggren, H. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12876 · Cited by 61
Ascierto, P. A., Fox, B. A., Urba, W. J., Anderson, A. C., Atkins, M. B., Borden, E. C., Brahmer, J. R., Butterfield, L. H., Cesano, A., Chen, D. S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000878 · Cited by 61
Malki, M. M. A., Tsai, N., Palmer, J. M., Mokhtari, S., Tsai, W., Cao, T. M., Ali, H., Salhotra, A., Arslan, S., Aldoss, I. T., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004192 · Cited by 60
Time to evolve: predicting engineered T cell-associated toxicity with next-generation models
Donnadieu, E., Luu, M., Alb, M., Anliker, B., Arcangeli, S., Bonini, C., Angelis, B. D., Choudhary, R., Espie, D., Galy, A. H. M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003486 · Cited by 66
Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR
Perales, M.-A., Kebriaei, P., Kean, L. S., & Sadelain, M. (2018) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2017.10.017 · Cited by 59
Tasian, S. K. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718774268 · Cited by 60
Complications after CD19+ CAR T-Cell Therapy
Penack, O., & Koenecke, C. (2020) · Cancers · doi:10.3390/cancers12113445 · Cited by 59
Machine Learning-Based Protein Microarray Digital Assay Analysis
Song, Y., Zhao, J., Cai, T., Stephens, A., Su, S., Sandford, E., Flora, C., Singer, B. H., Ghosh, M., Choi, S. W., et al. (2020) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113088 · Cited by 59
Jin, Z., Xiang, R., Qing, K., Li, X., Zhang, Y., Wang, L., Zhu, H., Mao, Y., Xu, Z., & Li, J. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3368-8 · Cited by 59
Clinical and Immunological Factors That Distinguish COVID-19 From Pandemic Influenza A(H1N1)
Choreño-Parra, J. A., Jiménez-Álvarez, L. A., Cruz‐Lagunas, A., Rodríguez-Reyna, T. S., Ramírez-Martínez, G., Sandoval-Vega, M., Hernández-García, D. L., Choreño-Parra, E. M., Balderas-Martínez, Y. I., Martínez-Sánchez, M. E., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.593595 · Cited by 62
No free rides: management of toxicities of novel immunotherapies in ALL, including financial
Jain, T., & Litzow, M. R. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018020198 · Cited by 58
Feasibility of real-time in vivo 89Zr-DFO-labeled CAR T-cell trafficking using PET imaging
Lee, S. H., Soh, H., Chung, J. H., Cho, E. H., Lee, S. J., Ju, J.-M., Sheen, J. H., Kim, H., Oh, S. J., Lee, S.-J., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0223814 · Cited by 59
Implications of High Tumor Burden on Chimeric Antigen Receptor T-Cell Immunotherapy
Ventin, M., Cattaneo, G., Maggs, L., Arya, S., Wang, X., & Ferrone, C. R. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.4504 · Cited by 64
Chimeric antigen receptor T‐cell therapies: Optimising the dose
Dasyam, N., George, P., & Weinkove, R. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14281 · Cited by 58
Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients
Mahmood, S., Riedell, P. A., Feldman, S. A., George, G., Sansoterra, S. A., Althaus, T., Rehman, M., Mead, E., Liu, J. E., Devereux, R. B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad117 · Cited by 56
Markouli, M., Ullah, F., Unlu, S., Omar, N., Lopetegui-Lia, N., Duco, M. R., Anwer, F., Raza, S., & Dima, D. (2023) · Current Oncology · doi:10.3390/curroncol30070467 · Cited by 51
Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer
Heng, W., Wang, Z., Kuang, Y., Wu, Z., Zhao, S., Zhang, Z., Li, H., Zheng, M., Zhang, N., Long, C., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.573823 · Cited by 56
Raj, R. V., Hamadani, M., Szabó, A., Pasquini, M. C., Shah, N. N., Drobyski, W. R., Shaw, B. E., Saber, W., Rizzo, J. D., Jerkins, J. H., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.04.010 · Cited by 55
Metadata
- Authors
- Teachey, D. T., Lacey, S. F., Shaw, P. A., Melenhorst, J. J., Maude, S. L., Frey, N., Pequignot, E., Gonzalez, V. E., Chen, F., Finklestein, J., Barrett, D. M., Weiss, S. L., Fitzgerald, J. C., Berg, R. A., Aplenc, R., Callahan, C., Rheingold, S. R., Zheng, Z., Rose-John, S., White, J. C., Nazimuddin, F., Wertheim, G., Levine, B. L., June, C. H., Porter, D. L., & Grupp, S. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- University of Pennsylvania (US)
- 10Institute of Biochemistry, CAU Kiel, Germany.
- Alexander T. Augusta Military Medical Center (US)
- Corresponding author
- Teachey, David T.
- ORCID
- Teachey, David T.
- Lacey, Simon F.
- Shaw, Pamela A.
- Melenhorst, J. Joseph
- Maude, Shannon L.
- Frey, Noelle
- Gonzalez, Vanessa E.
- Chen, Fang
- Barrett, David M.
- Weiss, Scott L.
- Fitzgerald, Julie C.
- Berg, Robert A.
- Aplenc, Richard
- Callahan, Colleen
- Rheingold, Susan R.
- Zheng, Zhaohui
- Wertheim, Gerald
- Levine, Bruce L.
- June, Carl H.
- Porter, David L.
- Grupp, Stephan A.
- Venue
- Cancer Discovery
- Published
- 2016-06-01
- Volume
- 6
- Issue
- 6
- Pages
- 664-679
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC5448406
- OpenAlex
- W2340435799
- Cited by
- 1,102
- References
- 35
- Citations by year
- 2026: 72 · 2025: 116 · 2024: 94 · 2023: 110 · 2022: 102 · 2021: 142 · 2020: 181 · 2019: 103 · 2018: 93 · 2017: 64 · 2016: 22
- FWCI
- 50.70
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA165206, R01CA102646, R01CA116660, R01CA193776, P30CA016520)
- National Institute of General Medical Sciences (K23GM110496)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- cytokine release syndrome, CAR T-cell therapy, acute lymphoblastic leukemia, CD19 CAR T cells, tisagenlecleucel, predictive biomarkers, cytokine profiling, interferon-gamma, interleukin-6, soluble gp130, C-reactive protein, ferritin, relapsed/refractory leukemia, toxicity prediction
- MeSH terms
- Adolescent, Adult, Aged, Child, Child, Preschool, Female, Humans, Immunotherapy, Male, Middle Aged, Phenotype, Prognosis, Receptors, Antigen, T-Cell, ROC Curve, Severity of Illness Index, Tumor Lysis Syndrome, Biomarkers, Cytokines, Treatment Outcome, Antigens, CD19, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Young Adult, Antibodies, Monoclonal, Humanized, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
